marimastat has been researched along with gi 129471 in 1 studies
| Studies (marimastat) | Trials (marimastat) | Recent Studies (post-2010) (marimastat) | Studies (gi 129471) | Trials (gi 129471) | Recent Studies (post-2010) (gi 129471) |
|---|---|---|---|---|---|
| 215 | 28 | 53 | 10 | 0 | 0 |
| Protein | Taxonomy | marimastat (IC50) | gi 129471 (IC50) |
|---|---|---|---|
| Interstitial collagenase | Homo sapiens (human) | 0.02 | |
| Low affinity immunoglobulin epsilon Fc receptor | Homo sapiens (human) | 0.04 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 5.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barlaam, B; Bird, TG; Campbell, D; Foster, SJ; Lambert-Van Der Brempt, C; Maciewicz, R | 1 |
1 other study(ies) available for marimastat and gi 129471
| Article | Year |
|---|---|
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
Topics: ADAM Proteins; ADAM17 Protein; Administration, Oral; Animals; Callithrix; Humans; Hydroxamic Acids; Metalloendopeptidases; Protease Inhibitors; Quinazolines; Succinates; Tumor Necrosis Factor-alpha | 1999 |